Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biogen Inc (BIIB)

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 43,263,776
  • Shares Outstanding, K 158,313
  • Annual Sales, $ 14,378 M
  • Annual Income, $ 5,889 M
  • 60-Month Beta 0.55
  • Price/Sales 2.97
  • Price/Cash Flow 6.99
  • Price/Book 3.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/20
See More
  • Average Estimate 8.27
  • Number of Estimates 27
  • High Estimate 9.62
  • Low Estimate 7.61
  • Prior Year 9.17
  • Growth Rate Est. (year over year) -9.81%

Price Performance

See More
Period Period Low Period High Performance
1-Month
265.05 +3.11%
on 09/21/20
288.03 -5.12%
on 09/02/20
-5.75 (-2.06%)
since 08/25/20
3-Month
257.60 +6.09%
on 06/26/20
312.00 -12.41%
on 08/07/20
+10.65 (+4.06%)
since 06/25/20
52-Week
219.70 +24.39%
on 10/03/19
374.99 -27.12%
on 02/05/20
+37.38 (+15.85%)
since 09/25/19

Most Recent Stories

More News
AC Immune's Candidate Fails in Alzheimer's Disease Study

The failure of AC Immune's (ACIU) study on Alzheimer's disease brings this challenging but promising space in focus.

BIIB : 273.28 (+1.20%)
RHHBY : 44.8200 (+0.27%)
NVS : 87.11 (+0.94%)
ACIU : 4.78 (-1.34%)
Global Pharma and Biotech Preclinical Stage Partnering Report 2020: Access 1,800+ Partnering Deals Announced Since 2014

, /PRNewswire/ -- The report has been added to offering.

AMGN : 243.82 (+1.46%)
BIIB : 273.28 (+1.20%)
CELGZ : 0.47 (+2.15%)
MRK : 82.93 (-0.26%)
NVS : 87.11 (+0.94%)
Biogen to Invest $250 Million in a 20-year Initiative to Eliminate its Use of Fossil Fuels and Improve Public Health

- After achieving carbon neutrality in 2014, Biogen further bolsters its action against climate change with the goal to become fossil fuel free by 2040 and initiates research collaborations with global...

BIIB : 273.28 (+1.20%)
New Data at ACTRIMS-ECTRIMS Meeting Showcase Safety and Efficacy of Biogen's Industry-Leading MS Portfolio

- New data from ongoing Phase 3 study further define the effectiveness and improved GI tolerability of VUMERITY(R) (diroximel fumarate)

BIIB : 273.28 (+1.20%)
Roche Expands Multiple Sclerosis Portfolio, Starts Studies

Roche (RHHBY) expands its MS portfolio by adding pipeline candidate, fenebrutinib. The company also initiates MS studies on fenebrutinib and Ocrevus.

BIIB : 273.28 (+1.20%)
RHHBY : 44.8200 (+0.27%)
GSK : 37.80 (+1.12%)
NVS : 87.11 (+0.94%)
New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS

-- Real-world data from MS PATHS identifies clinically relevant benchmarks to predict employment status among people with multiple sclerosis (MS)

BIIB : 273.28 (+1.20%)
New Biogen Data Presented at ACTRIMS-ECTRIMS Advance Understanding of Clinical and Health Disparities in MS

- Data highlights socio-demographic and clinical disparities to help raise awareness of health inequities and inform future treatment planning

BIIB : 273.28 (+1.20%)
OneUnited Bank, Fintech Pioneer, Announces $10 Million Deposit By Biogen To Support #BankBlack Movement

, /PRNewswire/ -- OneUnited Bank, the largest Black-owned bank in America, today announced that Biogen Inc. (Nasdaq: BIIB), a global biotechnology company, is investing to support the cutting-edge fintech's...

BIIB : 273.28 (+1.20%)
PTC Therapeutics Gets First Milestone Payment for SMA Drug

PTC Therapeutics (PTCT) gets first commercial milestone payment from Roche for first commercial sale of Evrysdi in the United States.

BIIB : 273.28 (+1.20%)
RHHBY : 44.8200 (+0.27%)
NVS : 87.11 (+0.94%)
PTCT : 46.60 (+0.47%)
AbbVie Seeks FDA Approval for Rinvoq in Ankylosing Spondylitis

AbbVie (ABBV) files an application to the FDA, seeking its nod for a new indication of Rinvoq, which is active ankylosing spondylitis. The drug is already marketed to treat rheumatoid arthritis.

BIIB : 273.28 (+1.20%)
NVS : 87.11 (+0.94%)
AMGN : 243.82 (+1.46%)
ABBV : 86.23 (+0.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 278.44
1st Resistance Point 275.86
Last Price 273.28
1st Support Level 269.10
2nd Support Level 264.92

See More

52-Week High 374.99
Fibonacci 61.8% 315.67
Fibonacci 50% 297.35
Fibonacci 38.2% 279.02
Last Price 273.28
52-Week Low 219.70

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar